Ceramide Transfer Protein (CERTL) - Blocking Peptide

  • Catalog name: X2380B
  • Supplier name: nordc
  • Size: 50 μg
  • Price: 168.00€
  • Category Proteins & Peptides
  • Long description CERT mediates the ATP-dependent ER-to-Golgi transfer of ceramide in a non-vesicular manner. The biosynthesis of lipids involves steps that occur in different intracellular compartments. The movement of lipids within these compartments is important in lipid-mediated signalling. Human CERT is identical to a splice variant of human Goodpasture antigen-binding protein (GPBP26)._x000B__x000B__x000B_CERT contains a phosphoinositide-binding pleckstrin-homology (PH) domain (which targets CERT to the Golgi by binding phosphatidylinositol-4-phosphate (PtdIns4P)), a middle region, and a putative lipid-transfer-catalysing domain called START. CERT and CERTL can specifically extract ceramide from phospholipid bilayers in a START-domain-dependent manner. CERT interacts with ER membranes and specifically extracts ceramide. CERT catalyses both the specific extraction of ceramide from donor vesicles and its transfer to acceptor vesicles. CERT can associate with the Golgi in a PtdIns4P dependent manner. _x000B_
  • Antibody come from Synthetic peptide derived from the N-terminal of the beta-actin protein.
  • Other description Provided as solution in phosphate buffered saline with 0.08% sodium azide.
  • Clone not specified
  • Antigen-antibody binding interaction Ceramide Transfer Protein (CERTL) - Blocking Peptide
  • Antibody is raised in Rabbit
  • Antibody's reacts with Human
  • Antibody's reacts with these species This antibody doesn't cross react with other species
  • Antibody's specificity No Data Available
  • Application Western Blot
  • Antibody's suited for Antibody can be used for Western blotting (1-5 µg/ml). Optimal concentration should be evaluated by serial dilutions.
  • Storage -20ºC
  • Relevant references 1. Ponte P., Ng S.Y., Engel J., Gunning P., Kedes L., Evolutionary conservation in the untranslated regions of actin mRNAs: DNA sequence of a human beta-actin cDNA._x000B_Nucleic Acids Res. 12:1687-1696(1984)_x000B__x000B_2. Nakajima-Iijima S., Hamada H., Reddy P., Kakunaga T.,Molecular structure of the human cytoplasmic beta-actin gene: interspecies homology of sequences in the introns._x000B_Proc. Natl. Acad. Sci. U.S.A. 82:6133-6137(1985)_x000B__x000B_3. Procaccio V., Salazar G., Ono S., Styers M.L., Gearing M., Davila A., Jimenez R., Juncos J., Gutekunst C.-A., Meroni G., Fontanella B., Sontag E., Sontag J.-M., Faundez V., Wainer B.H. A mutation of beta -actin that alters depolymerization dynamics is associated with autosomal dominant developmental malformations, deafness, and dystonia. Am. J. Hum. Genet. 78:947-960(2006) [PubMed: 16685646] [Abstract]
  • Protein number see ncbi
  • Warnings This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. This datasheet is as accurate as reasonably achievable, but Nordic-MUbio accepts no liability for any inaccuracies or omissions in this information.
  • Test You can block the antibody by the specific target amino acid sequence of peptide.
  • Properties blocking peptide